V
The FDA’s peptide circus is underway.
An advisory panel, stacked with RFK Jr.’s pro-peptide appointees, has voted to add BPC-157 and KPV to the bulk compounding list. This is despite FDA staff clinicians stating that there’s no convincing evidence. Central to the argument is whether allowing compounding will curtail the gray market or expose the public to unnecessary risk. Internally screaming.
Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.
Loading comments
Getting the conversation ready...
Most Popular
Most Popular
- OpenAI pauses training of its ‘most capable models’
- Leaks reveal a new Apple HomePod mini, iPad mini, and Apple TV 4K
- Can Apple Home’s AI camera features outsmart Amazon’s and Google’s? I put them to the test
- Can ‘eSUV’ e-bikes really go from trail to town?
- Gemini 4 is almost ready, says new Google DeepMind chief
